Literature DB >> 16320087

Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition.

Bryan D Devan1, Jonna L Bowker, Kara B Duffy, Ila S Bharati, Mariana Jimenez, Demetrio Sierra-Mercado, Christopher M Nelson, Edward L Spangler, Donald K Ingram.   

Abstract

RATIONALE: The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signal transduction pathway has been implicated in some forms of learning and memory. Recent findings suggest that inhibition of phosphodiesterase (PDE) enzymes that degrade cGMP may have memory-enhancing effects.
OBJECTIVES: We examined whether treatment with sildenafil citrate, a PDE type 5 inhibitor, would attenuate a learning impairment induced by inhibition of NO synthase [60 mg/kg N(omega)-nitro-L-arginine methyl ester (L-NAME), i.p.].
METHODS: Rats were pretrained in a one-way active avoidance of foot shock in a straight runway and, on the next day, received 15 training trials in a 14-unit T-maze, a task that has been shown to be sensitive to aging and impairment of central NO signaling systems. Combined treatments of L-NAME or saline and sildenafil (1.0, 1.5, 3.0, or 4.5 mg/kg, i.p.) or vehicle were given 30 and 15 min before training, respectively. Behavioral measures of performance included entries into incorrect maze sections (errors), run time from start to goal (latency), shock frequency, and shock duration.
RESULTS: Statistical analysis revealed that L-NAME impaired maze performance and that sildenafil (1.5 mg/kg) significantly attenuated this impairment. Control experiments revealed that administration of L-NAME alone did not significantly increase latencies in a one-way active avoidance test and that different doses of sildenafil alone did not significantly alter complex maze performance.
CONCLUSIONS: The results indicate that sildenafil may improve learning by modulating NO-cGMP signal transduction, a pathway implicated in age-related cognitive decline and neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16320087     DOI: 10.1007/s00213-005-0232-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

Review 1.  Memory--a century of consolidation.

Authors:  J L McGaugh
Journal:  Science       Date:  2000-01-14       Impact factor: 47.728

2.  Alteration of nitric oxide synthase activity in young and aged apolipoprotein E-deficient mice.

Authors:  A Law; S Gauthier; R Quirion
Journal:  Neurobiol Aging       Date:  2003 Jan-Feb       Impact factor: 4.673

Review 3.  Enriched environment, nitric oxide production and synaptic plasticity prevent the aging-dependent impairment of spatial cognition.

Authors:  Silvia Lores Arnaiz; Gabriela D'Amico; Nora Paglia; Mariana Arismendi; Nidia Basso; María del Rosario Lores Arnaiz
Journal:  Mol Aspects Med       Date:  2004 Feb-Apr

4.  Catalepsy and hypolocomotion induced by a nitric oxide donor: attenuation by theophylline.

Authors:  O P Dall'Igna; M O Dietrich; A Hoffmann; W Neto; D Vendite; D O Souza; D R Lara
Journal:  Eur J Pharmacol       Date:  2001-11-30       Impact factor: 4.432

5.  Nitric oxide synthase in rat brain: age comparisons quantitated with NADPH-diaphorase histochemistry.

Authors:  H Kuo; J Hengemihle; D K Ingram
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1997-05       Impact factor: 6.053

6.  The effects of chronic administration of nimodipine on age-related changes in nitric oxide and its synthase in senescence-accelerated mouse brain.

Authors:  K Inada; I Yokoi; H Kabuto; Y Namba; N Ogawa
Journal:  Biochem Mol Biol Int       Date:  1997-04

Review 7.  New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment.

Authors:  D K Ingram; E L Spangler; S Iijima; H Kuo; E L Bresnahan; N H Greig; E D London
Journal:  Ann N Y Acad Sci       Date:  1994-06-30       Impact factor: 5.691

8.  Hippocampal nitric oxide upregulation precedes memory loss and A beta 1-40 accumulation after chronic brain hypoperfusion in rats.

Authors:  J C de la Torre; B A Pappas; V Prevot; M R Emmerling; K Mantione; T Fortin; M D Watson; G B Stefano
Journal:  Neurol Res       Date:  2003-09       Impact factor: 2.448

9.  Scopolamine in rats impairs acquisition but not retention in a 14-unit T-maze.

Authors:  E L Spangler; M E Chachich; D K Ingram
Journal:  Pharmacol Biochem Behav       Date:  1988-08       Impact factor: 3.533

10.  Differential effects of L-NAME on blood pressure and heart rate responses to acetylcholine and bradykinin in cynomolgus primates.

Authors:  S M Weldon; R J Winquist; J B Madwed
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

View more
  20 in total

Review 1.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 2.  Neurorestorative treatment of stroke: cell and pharmacological approaches.

Authors:  Jieli Chen; Michael Chopp
Journal:  NeuroRx       Date:  2006-10

3.  Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease.

Authors:  M Cuadrado-Tejedor; I Hervias; A Ricobaraza; E Puerta; J M Pérez-Roldán; C García-Barroso; R Franco; N Aguirre; A García-Osta
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

4.  Age-related impairment of cerebral blood flow response to KATP channel opener in Alzheimer's disease mice with presenilin-1 mutation.

Authors:  Dong Liu; Ismayil Ahmet; Brandon Griess; David Tweedie; Nigel H Greig; Mark P Mattson
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-17       Impact factor: 6.200

5.  Striatal lesions interfere with acquisition of a complex maze task in rats.

Authors:  Paul J Pistell; Chris M Nelson; Marshall G Miller; Edward L Spangler; Donald K Ingram; Bryan D Devan
Journal:  Behav Brain Res       Date:  2008-08-22       Impact factor: 3.332

6.  NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.

Authors:  Samer O Abdul-Hay; Jia Luo; Rezene T Ashghodom; Gregory R J Thatcher
Journal:  J Neurochem       Date:  2009-08-21       Impact factor: 5.372

Review 7.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

Review 8.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  A placebo-controlled study of sildenafil effects on cognition in schizophrenia.

Authors:  Donald C Goff; Corinne Cather; Oliver Freudenreich; David C Henderson; A Eden Evins; Melissa A Culhane; Jared P Walsh
Journal:  Psychopharmacology (Berl)       Date:  2008-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.